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ABSTRACT
Objective: A rapid, sensitive, selective, and reproducible reversed-phase high-performance liquid chromatographic method has been developed and 
validated for the determination of crizotinib (CRZ), a tyrosine kinase inhibitor for targeted therapy of anaplastic lymphoma kinase-positive non-small-
cell lung cancer.
Methods: The chromatographic separation was carried out in an isocratic mode on an YMC ODS C18 column with a mobile phase consisting of 
methanol and water containing 0.1% orthophosphoric acid in the ratio of 50:50 v/v at a flow rate of 0.6 ml/min. The run time was maintained for 
10 min and detection was monitored at 267 nm. The method involved reproducible liquid-liquid extraction of drug from human plasma using diethyl 
ether as extracting solvent.
Results: CRZ and internal standard retention times were 6.86 and 7.94 min, respectively. Calibration curves were linear over a concentration range 
of 20.41–2041.14 ng/ml with correlation coefficient 0.9994. The lower limit of quantification for CRZ in plasma was 20 ng/ml. No endogenous 
substances were found to interfere with the peaks of drug and internal standard. The intra- and inter-day precision was <9.0% and the accuracy 
ranged from 97% to 112% over the linear range. All stability studies showed that CRZ in plasma sample was stable.
Conclusion: This method was found to be simple, selective, precise, accurate, and cost-effective. Hence, the method can be successfully applied to 
analyze the CRZ concentration in plasma samples for pharmacokinetic and bioequivalence studies.
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INTRODUCTION
Anaplastic lymphoma kinase (ALK) is a receptor-type tyrosine kinase 
that belongs to the insulin receptor superfamily and alterations in the 
ALK gene including chromosomal translocations have been implicated 
in the development of ALK-positive human cancers. Crizotinib (CRZ) 
is an orally available aminopyridine-based inhibitor of the receptor 
tyrosine kinase ALK and the c-met/hepatocyte growth factor receptor 
with antineoplastic activity [1]. CRZ (Fig. 1) is the first targeted therapy 
for the treatment of ALK-positive non-small-cell lung cancer [2,3]. In a 
Phase I pharmacokinetic study evaluation of CRZ, a single 250 mg dose 
achieved a maximum drug concentration in 4 h following the dose, 
with a mean apparent terminal half-life of approximately 42 h [4]. At 
present, a combination of CRZ and dasatinib is being used for treating 
high-grade glioma. Due to pharmacokinetic interaction between these 
drugs, as CRZ is an inhibitor of cytochrome P4503A. Hence, a reliable 
and sensitive analytical method for the determination of CRZ is much 
needed for further pharmacokinetic studies. Literature review revealed 
that CRZ was assayed in plasma by liquid chromatography coupled 
with tandem mass spectrometry [5-9], fluorescence detection [10]. 
Spectrofluorimetry was reported in biological fluids [11]; high-
performance liquid chromatography (HPLC) method has been 
reported for the determination of CRZ in dosage form [12]. Although 
some of these methods provide high sensitivity and specificity, tedious 
extraction techniques and expensive technology are a major hindrance 
for their practical implementation. Therefore, a simple HPLC method 
with a routine extraction procedure is desirable. Hence, the present 
work was designed to develop and validate an HPLC method with 




CRZ (purity 98.00% w/w) was purchased from Celon Laboratories 
(P) Ltd., zidovudine (used as internal standard, purity 99.5% w/w) 
is purchased from Hetero Drugs Ltd., Hyderabad, India. Methanol, 
acetonitrile (HPLC grade), orthophosphoric acid, and diethyl ether 
were purchased from Merck Ltd., Mumbai, India. All the other reagents 
used were analytical grade. All aqueous solutions were prepared using 
deionized water, processed through a Milli-Q water purification system 
(Millipore, USA). Human K3 ethylenediaminetetraacetic acid (EDTA) 
plasma was collected from Sri Laxmi Sai Clinic, Hyderabad, India.
Instrument and chromatographic conditions
The chromatographic system consisted of a Shimadzu Class VP Binary 
pump LC 10ATvp, SIL-10ADvp autosampler, CTO-10Avp Column 
Temperature Oven, and SPD-10Avp UV-Visible detector. All the 
components of the system were controlled using SCL-10Avp System 
Controller. Data acquisition was done using LC solutions software. 
Chromatographic separations were accomplished using an YMC 
ODS C18 (250 mm×4.6 mm, 5 µm) column. All determinations were 
carried out at room temperature. The mobile phase was composed of 
a mixture of 50 parts of methanol and 50 parts of water (containing 
0.1% orthophosphoric acid). The mixture was filtered through a 
0.45 µm Whatman membrane filter under vacuum and then degassed 
by ultrasonication. The mobile phase was pumped isocratically at a flow 
rate of 0.6 ml/min during analysis at ambient temperature. Peaks were 
monitored by a UV detector adjusted at 267 nm. Quantification of CRZ 
was obtained by plotting CRZ to internal standard peak area ratios as a 
function of concentrations.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29272
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Calibration and quality control (QC) sample preparations
Stock solutions were prepared by dissolving CRZ and IS in methanol to a 
concentration of 1 mg/ml. The stock solution of CRZ was further diluted 
with 50% (v/v) aqueous methanol to get working standard solutions 
having concentrations of 0.41, 1.63, 8.16, 24.49, 32.66, and 40.82 µg/ml. 
Aliquots of 950 µl of drug-free K3-EDTA human plasma were spiked 
with 50 µL of working standard solutions to get calibration curve 
(CC) standards containing 20.41, 81.65, 408.23, 1224.68, 1632.91, 
and 2041.14 ng/ml of CRZ. QC samples were prepared separately 
and pooled at three different concentrations level (61.23, 995.05, and 
1439.00 ng/ml) as low, medium, and high QC (LQC, MQC, and HQC) 
samples, respectively, to evaluate the intra- and inter-precision and 
accuracy of this method. All samples were stored in a freezer at −20°C 
until analysis.
Sample preparation
The extraction of the plasma samples involved liquid-liquid extraction 
(LLE) process. For processing, the stored spiked samples were withdrawn 
from the freezer and allowed to thaw at room temperature. An aliquot 
of 200 µl was then transferred to pre-labeled 2.0 ml polypropylene 
centrifuge tubes. Internal standard dilution, 25 µl (5 µg/ml) was then 
added and mixed. To this solution, 1.0 ml of diethyl ether was added 
to extract the drug and internal standard. The samples were then kept 
on a reciprocating shaker and allowed to mix for 20 min. Samples were 
then centrifuged at 5000 rpm for 5 min to effect phase separation. The 
supernatant solution, 0.8 ml was then transferred into pre-labeled 
polypropylene tubes and was allowed to evaporate to dryness under 
a nitrogen atmosphere at the constant temperature of 40°C. The dried 
residue was then dissolved in 100 µl of mobile phase and transferred 
into vials for chromatographic analysis. The autosampler temperature 
was maintained at 4°C throughout the analysis.
Validation of quantitative HPLC method
The reversed-phase HPLC (RP-HPLC) method was validated according to 
the US Food and Drug Administration (FDA) guidelines on bioanalytical 
method validation [13]. The following parameters were evaluated: 
Selectivity, CC regression model, accuracy and precision, recovery from 
biosamples, the stability of analyte in the stock solution under the entire 
period of storage, and processing conditions. Selectivity was designed 
to investigate whether endogenous constituents and other substances 
in existing samples would interfere with the detection of CRZ and IS. It 
was studied by comparing the chromatograms of six different batches 
of human blank plasma with the corresponding spiked plasma.
The linearity of the CC in human plasma was confirmed by plotting the 
Peak area ratio of drug/IS versus the corresponding CRZ concentration 
with least squares linear regression analysis. Interday and intraday 
accuracy and precision were evaluated by analysis of QCs at three levels. 
The recoveries of CRZ from the extracted samples were estimated by 
correlating the known concentrations of plasma samples. This whole 
process was recapitulated for concentration levels of 61.23, 995.05, 
and 1439.00 ng/ml, which represent the LQC, MQC, and HQC standards, 
respectively [14].
The chemical stability of any compound in stock solution and biological 
samples is a critical parameter for its further development. Stock 
solution stability, freeze-thaw stability, benchtop stability, autosampler 
stability, and long-term stability was conducted to determine the 
stability of CRZ in plasma. For the determination of CRZ stability, spiked 
controls in human plasma were made at 61.23 and 1439.00 ng/ml 
concentrations, representing LQC and HQC, respectively, each with three 
sets of replicates.
RESULTS AND DISCUSSION
Several parameters were examined for the optimization of HPLC analysis 
of CRZ in human plasma. Optimization was achieved by monitoring 
varying RP columns, mobile phase systems, flow rate, wavelength, and 
using the extraction method. The first step in method development 
was the selection of the optimal analytical column. Different columns 
were tested for their ability to separate the analyte. The columns that 
were tested included an Agilent Zorbax C18, Phenomenex Prodigy 
(150 mm×4.6 mm i.d), Phenomenex C18 (250×4.6 mm i.d), and finally, 
an YMC ODS C18 (250 mm×4.6 mm i.d) column, which provided the 
best separation efficiency. For the mobile phase, different mixtures of 
methanol, acetonitrile, and water were tested. The mobile phase that 
gave optimal separation from plasma endogenous peaks was a 50:50 
mixture of methanol and water containing 0.1% orthophosphoric acid 
(v/v). The flow rate of the method was optimized at 0.6 ml/min. The 
column temperature was maintained at 25°C. In addition to this, UV 
spectra of individual drugs were recorded in the wavelength range 
from 200 nm to 400 nm. The choice of the wavelength of 267 nm was 
considered satisfactory, permitting the detection of CRZ with adequate 
sensitivity. This analytical method requires simple chromatographic 
conditions including the use of mobile phases with the small percentage 
of organic solvent in the absence of gradient programs [15].
It was difficult to find a compound to be used as an internal standard. 
Different compounds were investigated such as emtricitabine, 
suvorexant, metoprolol, levofloxacin, and valsartan. However, these 
drugs have long retention time or highly broad peaks, eluted early, and 
interfered with CRZ or plasma peaks. Finally, zidovudine was found 
to be the most appropriate internal standard under the separation 
condition. For the biological samples cleanup, some of the HPLC 
methods used methanol or acetonitrile to precipitate the protein. The 
advantages of this procedure are speed and ease, but the disadvantage 
is incomplete precipitation of the plasma protein; also, the final organic 
phase contains not only endogenous substances that are soluble in the 
solvent but also some water-soluble compounds which badly affect 
separation efficiency and may damage HPLC column [16].
When LLE was performed, using different solvents were tert-butyl 
methyl ether, ethyl acetate, dichloromethane, and hexane, it was 
observed that both the analyte and IS were comparably extracted and 
good recovery was obtained with diethyl ether. LLE method is usually 
devoid of polar interferences, thus rendering the sample clean for 
analysis. The noise is usually absent or at the minimum as compared 
to precipitation technique. It requires an only a small volume of plasma 
(200 µl). Due to the LLE method of extraction, the baseline noise is 
minimal. Matrix effects are not observed. Under the chromatographic 
conditions described, the retention time for extracted peaks of CRZ and 
IS was 6.86 and 7.94 min, respectively.
Selectivity
Typical chromatograms obtained from blank human plasma and the 
plasma spiked with CRZ and IS are shown in Fig. 2, which indicates that 
no peak of any endogenous compound appeared at the retention time 
of CRZ and zidovudine.
Fig. 1: Chemical structure of crizotinib
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Linearity
The linearity was determined from the constructed standard Calibration 
curve (CC). The upper limit of quantification value was taken as 
2041.14 ng/ml since the plasma concentration of CRZ is lower than this 
value after its oral administration. Six non-zero samples (20.41, 81.65, 
408.23, 1224.68, 1632.91, and 2041.14 ng/ml) including the lower limit 
of quantification (LLOQ) (20 ng/ml) were used to draw the standard CC 
(n=3). The CC was obtained by plotting chromatographic peak area ratio 
(CRZ/zidovudine) versus concentration of CRZ (Fig. 3). Samples were 
prepared and analyzed on the same day. The correlation coefficient r2 was 
found to be 0.9994 (Table 1). The back-calculated concentrations of the 
calibration standards were within ±15% of the nominal value, meeting the 
FDA guidelines.
Accuracy and precision
Accuracy and precision of the method were evaluated using six replicates 
of QC samples (LLOQ, LQC, MQC, and HQC) as a lower limit, low, medium, 
and high concentration levels. The samples were analyzed against the CC, 
and the obtained concentrations were compared with the nominal value. 
The percentage CV was calculated forth replicates precision. Both accuracy 
and precision were studied within a single run (intra) and between 
different runs (interday), each of them was compared to the calibrations 
performed. The within-day percentage CV ranged from 1.05% to 8%, 
whereas, the between day percentage CV ranged from 2.0% to 7%. The 
intraday accuracy ranged between 97% and 104%, whereas the interday 
accuracy ranged between 99 and 106%. The obtained results (Table 2) 
indicated satisfactory accuracy and precision of the proposed method.
Recovery
The percentage recovery of CRZ was measured by dividing the peak 
area values of extracted QC samples with direct injection of a solution 
containing the same nominal concentration of compounds as the 
QC samples in extracted blank plasma. Overall, the results for CRZ 
Fig. 3: Calibration curve of crizotinib
Table 1: Linear regression data for CC (n=3)
Parameter Values
Absorption maxima (nm) 267
Linearity range (ng/ml) 20.41–2041.14
Quantification limit (ng/ml) 20.41
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absolute recovery from human plasma were tested at three different 
concentration levels (LQC, MQC, and HQC) were 61.56 %, 67.09%, 
and 76.20%, respectively. The results of the recovery studies of CRZ 
are represented in Table 3. The mean recovery of CRZ was 68.29% 
with a coefficient of the variation of 3.80% (n=3). Internal standard 
recovery at 2.5 µg/ml of zidovudine was 56.12% with a coefficient of 
the variation of 1.10%.
Stability
Analysis of the stock solutions of CRZ and IS in methanol was stable for 
30 days at 2–8°C and at room temperature for 6 h, more than 97.5% 
of CRZ remained unchanged, based on peak areas in comparison with 
freshly prepared solution of CRZ. This suggests that the CRZ in standard 
solution is stable for at least 30 days when stored at 2−8°C and for 6 h 
at room temperature [17,18]. Stability of CRZ in plasma samples was 
investigated with spiked samples at two different concentration levels. 
Benchtop stability of CRZ in plasma was investigated at LQC and HQC 
levels. This revealed that the CRZ in plasma was stable for 6 h at room 
temperature. It was confirmed that repeated freezing and thawing 
(three cycles) of plasma samples spiked with CRZ were assessed by 
analyzing three replicates of QC at low and high level did not affect 
the stability of the drug. The freeze-thaw stability of CRZ after three 
cycles was 96.33% and 93.81% at low and high concentrations. Long-
term stability of the CRZ in plasma at −20°C was also performed after 
15 days of storage at LQC and HQC levels, and similarly, autosampler 
stability was studied following 48 h storage at 4°C in the autosampler 
tray with control concentrations. Further, no significant change in the 
chromatographic behavior of CRZ and IS was observed (Table 4). The 
above results indicated that the CRZ was stable under all conditions 
studied.
CONCLUSION
A selective, accurate, and precise RP-HPLC method for the estimation 
of CRZ in human plasma was successfully developed. The method met 
the validation criteria laid down by the US-FDA guidelines. The HPLC 
technique based on UV detection is suitable for the determination of 
small amounts of CRZ with good accuracy and reproducibility. Simple 
sample preparation procedure and relatively short chromatographic 
run time make this method suitable for processing multiple samples 
in a limited amount of time for pharmacokinetic studies. Hence, the 
developed method can be applied to pharmacokinetics studied and 
therapeutic drug monitoring in humans.
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